Key facts
- Toragen’s last known valuation is $35.4M (Sep 2022).
- It has raised $18.7M; the latest was Later Stage VC ($12.0M) in Oct 2025.
- Notable investors include Raptor Group, GenHenn Capital, Paul Engler, Steven Lebow.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Toragen
- ·The full record, as it builds
Funding rounds
No funding rounds for Toragen are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Toragen
Developer of an anti-viral drug intended to treat viral-associated cancers. The company's expertise includes translational drug development and practice-changing to the treatment of human papillomavirus-induced cancers, helping drug companies with novel therapeutics targeting oncogenic viruses.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2016
- Employees
- 7
- Website
- toragen.com/
- Ownership
- Privately Held (backing)
Toragen doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Toragen shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Toragen in its N-PORT filings yet. We sweep new filings monthly.